Target- |
Mechanism- |
|
|
|
|
Drug Highest PhasePhase 2 |
First Approval Ctry. / Loc.- |
First Approval Date- |
|
MechanismClass I PI3K inhibitors |
Active Org.- |
|
Active Indication- |
|
Drug Highest PhasePending |
First Approval Ctry. / Loc.- |
First Approval Date- |
评价伊匹乌肽滴眼液在神经营养性角膜炎患者中安全性和有效性的随机、双盲、安慰剂平行对照的多中心Ⅱ期临床试验
[Translation] A randomized, double-blind, placebo-controlled, multicenter phase II clinical trial to evaluate the safety and efficacy of ipiluvitide eye drops in patients with neurotrophic keratitis
以安慰剂为对照,初步评价伊匹乌肽滴眼液治疗神经营养性角膜炎的有效性和安全性。
[Translation] Using placebo as control, this study preliminarily evaluated the efficacy and safety of ipiluvitide eye drops in the treatment of neurotrophic keratitis.
伊匹乌肽滴眼液治疗干眼症的随机、双盲、安慰剂平行对照、单中心临床试验
[Translation] A randomized, double-blind, placebo-controlled, single-center clinical trial of ipilimumab eye drops in the treatment of dry eye
以安慰剂为对照,初步评价伊匹乌肽滴眼液治疗干眼症的有效性和安全性。
[Translation] Using placebo as a control, this study preliminarily evaluated the efficacy and safety of ipiluvitide eye drops in the treatment of dry eye.
伊匹乌肽滴鼻剂治疗常年性变应性鼻炎的随机、双盲、安慰剂平行对照、多中心临床试验
[Translation] A randomized, double-blind, placebo-controlled, multicenter clinical trial of ipilimumab nasal drops in the treatment of perennial allergic rhinitis
评价伊匹乌肽滴鼻剂治疗中-重度常年性变应性鼻炎的有效性和安全性
[Translation] To evaluate the efficacy and safety of ipilimumab nasal drops in the treatment of moderate to severe perennial allergic rhinitis
100 Clinical Results associated with Wuhan Yicheng Biotechnology Co., Ltd.
0 Patents (Medical) associated with Wuhan Yicheng Biotechnology Co., Ltd.
100 Deals associated with Wuhan Yicheng Biotechnology Co., Ltd.
100 Translational Medicine associated with Wuhan Yicheng Biotechnology Co., Ltd.